Cambrex Corporation (NYSE: CBM) has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE